> For the complete documentation index, see [llms.txt](https://www.thiamine.wiki/llms.txt). Markdown versions of documentation pages are available by appending `.md` to page URLs; this page is available as [Markdown](https://www.thiamine.wiki/biochemistry/mechanisms-of-malabsorption.md).

# mechanisms of malabsorption

{% hint style="info" %}
**Section:** Complete Biochemistry → Transporters & Absorption\
**Reading level:** Technical, with a plain-language summary\
**Last reviewed:** October 2026 · **Evidence status:** Well established (alcohol, bariatric surgery); moderate to limited (other conditions, labelled below)
{% endhint %}

## Summary

Absorbing thiamine requires several steps to work: thiamine must be released from food, reach a healthy stretch of small intestine, be carried into intestinal cells by transporters, and then exit into the blood. **Malabsorption** occurs when disease or treatment disrupts one or more of these steps.

The best-documented causes are **chronic alcohol use**, which suppresses the intestinal thiamine transporters, and **bariatric surgery**, which combines reduced intake, intestinal bypass and vomiting. Other causes include loss of absorptive surface, rapid transit, drugs that block the transporters, bacterial overgrowth and coexisting nutrient deficiencies. In practice, malabsorption usually combines with poor intake or increased losses rather than acting alone.

## The steps of absorption and how each can fail

| Step                                        | Normal process                                                | Failure modes                                                                                                                                                                    |
| ------------------------------------------- | ------------------------------------------------------------- | -------------------------------------------------------------------------------------------------------------------------------------------------------------------------------- |
| **1. Release from food**                    | Phosphatases convert dietary TPP and TMP to free thiamine     | Severe mucosal damage reducing brush-border enzyme activity; dietary thiaminases destroying thiamine (see [GI Factors](broken://pages/fa7b936a5a5b06d4438d7966f1ad6f33c65df7e7)) |
| **2. Contact with absorptive surface**      | Free thiamine reaches duodenum and jejunum                    | Surgical bypass; vomiting; rapid transit; reduced surface area                                                                                                                   |
| **3. Apical uptake**                        | THTR-2 and THTR-1 carry thiamine into enterocytes (saturable) | Reduced transporter expression (alcohol, inflammation); drug inhibition; genetic defects                                                                                         |
| **4. Intracellular handling**               | Thiamine crosses the enterocyte                               | Experimental evidence that alcohol impairs this stage                                                                                                                            |
| **5. Basolateral exit**                     | THTR-1 moves thiamine into blood                              | Suppression by alcohol (historical evidence)                                                                                                                                     |
| **6. Colonic uptake of microbial thiamine** | Colonocytes absorb bacterial thiamine and TPP                 | Colectomy; altered microbiota; contribution uncertain                                                                                                                            |

## Mechanisms in detail

### Reduced transporter function

| Cause                           | Mechanism                                                                                                                                   | Evidence                                                                                  |
| ------------------------------- | ------------------------------------------------------------------------------------------------------------------------------------------- | ----------------------------------------------------------------------------------------- |
| **Chronic alcohol use**         | Reduced expression of THTR-1 and THTR-2 in intestine (and kidney); older studies also showed impaired active transport and basolateral exit | **Strong**: human absorption studies, animal and cell models                              |
| **Drugs inhibiting THTR-2**     | Fedratinib, metformin and trimethoprim inhibit THTR-2 in vitro; intestinal THTR-2 is a plausible site of interaction                        | **Strong** in vitro; clinical significance established for fedratinib, unclear for others |
| **Genetic transporter defects** | *SLC19A2* mutations (TRMA) reduce THTR-1 function; absorption continues via THTR-2 and passive diffusion                                    | **Strong**                                                                                |
| **Inflammation**                | Experimental studies suggest inflammatory signals can reduce transporter expression                                                         | **Limited**                                                                               |

### Loss of absorptive surface or contact time

| Cause                                             | Mechanism                              | Evidence                                                           |
| ------------------------------------------------- | -------------------------------------- | ------------------------------------------------------------------ |
| **Short bowel syndrome**                          | Reduced length of absorptive intestine | **Moderate**; often combined with parenteral nutrition dependence  |
| **Coeliac disease (untreated)**                   | Villous atrophy reduces surface area   | **Limited** for thiamine specifically                              |
| **Crohn's disease affecting the small intestine** | Inflammation and resection             | **Limited to moderate**; thiamine status findings in IBD are mixed |
| **Chronic diarrhoea, rapid transit**              | Reduced contact time                   | **Moderate**, mainly physiological reasoning and case reports      |
| **Radiation enteritis, chemotherapy mucositis**   | Mucosal injury                         | **Limited**                                                        |

### Bariatric (weight-loss) surgery

Thiamine deficiency, including Wernicke encephalopathy, is well documented after bariatric surgery. Most cases occur in the first months after surgery and are associated with **persistent vomiting**. Contributing mechanisms include:

* **reduced food intake**;
* **bypass of the duodenum and proximal jejunum** in Roux-en-Y gastric bypass and biliopancreatic diversion, removing the main absorption site from the food stream;
* **pre-absorptive losses** from vomiting;
* **small intestinal bacterial overgrowth** in the bypassed or blind limb.

A study of patients after Roux-en-Y gastric bypass found that thiamine deficiency was associated with bacterial overgrowth and improved when the overgrowth was treated with antibiotics.

### Pre-absorptive losses

Vomiting (hyperemesis gravidarum, eating disorders, gastric outlet obstruction, post-surgical complications) removes thiamine before it reaches absorptive sites. Because thiamine stores are small, prolonged vomiting can cause deficiency within weeks.

### Small intestinal bacterial overgrowth (SIBO)

Bacteria in the small intestine can **compete for** thiamine. Some species produce thiaminases that **destroy** it. Evidence linking SIBO to clinical thiamine deficiency comes mainly from bariatric surgery studies and case reports. SIBO is a heterogeneous condition, and its effect on thiamine in other settings is not well characterized.

### Coexisting nutritional deficiencies

| Deficiency                      | Effect on thiamine absorption                                                                                   | Evidence                   |
| ------------------------------- | --------------------------------------------------------------------------------------------------------------- | -------------------------- |
| **Folate**                      | Folate-deficient rats showed impaired thiamine absorption, possibly through effects on intestinal cell turnover | **Limited** (animal data)  |
| **Protein-energy malnutrition** | Mucosal atrophy and reduced enzyme and transporter expression                                                   | **Moderate**               |
| **Magnesium**                   | Does not impair absorption, but impairs conversion of absorbed thiamine to TPP                                  | **Limited** (case reports) |

## Why alcohol is so damaging

Alcohol affects thiamine absorption in several ways:

* **Acute exposure** inhibits active thiamine transport.
* **Chronic exposure** lowers THTR-1 and THTR-2 messenger RNA and protein levels in intestinal cells.
* Classic studies in malnourished people with alcohol use disorder showed **reduced absorption of radiolabelled thiamine**, which improved after abstinence and nutritional repletion.
* Older work also implicated impaired **basolateral exit** from enterocytes.

These absorptive effects combine with poor intake, reduced hepatic storage, impaired phosphorylation and increased urinary loss (see [Causes of Deficiency](broken://pages/e2f0079872756b16d945a693f3b5e16abb5efad9)).

## Assessing malabsorption

There is **no routine clinical test** of thiamine absorption. In research, absorption has been studied with radiolabelled thiamine and by comparing blood or urine levels after oral and intravenous doses. In clinical practice, malabsorption is usually inferred from the underlying condition, low thiamine status despite apparently adequate intake, or response to non-oral routes.

## Routes around malabsorption (informational)

The following strategies are described in the literature. Choice of approach in any individual is a clinical decision.

| Strategy                                               | Rationale                                                                                                                                                               | Evidence                                                                                                                                                                       |
| ------------------------------------------------------ | ----------------------------------------------------------------------------------------------------------------------------------------------------------------------- | ------------------------------------------------------------------------------------------------------------------------------------------------------------------------------ |
| **Parenteral thiamine** (intravenous or intramuscular) | Bypasses the gut entirely                                                                                                                                               | **Strong**: standard in suspected Wernicke encephalopathy and severe malabsorption                                                                                             |
| **High oral doses**                                    | At high luminal concentrations, passive diffusion supplements carrier-mediated uptake; absorption continues to rise with dose up to at least 1,500 mg in healthy people | **Moderate**: pharmacokinetic data in healthy volunteers; less data in people with malabsorption                                                                               |
| **Lipid-soluble derivatives**                          | Absorbed largely independently of THTR-1/2                                                                                                                              | **Moderate** for higher blood levels; **limited** for clinical outcomes in malabsorption (see [Thiamine Derivatives](broken://pages/44390ee2e231e4f690942c9b807cab9f6eb7272d)) |
| **Treating the underlying cause**                      | For example, abstinence from alcohol, treatment of SIBO, gluten-free diet in coeliac disease                                                                            | Varies by condition                                                                                                                                                            |

## Evidence quality

| Claim type                                        | Strength                                                    |
| ------------------------------------------------- | ----------------------------------------------------------- |
| Alcohol suppressing intestinal thiamine transport | **Strong**                                                  |
| Bariatric surgery as a cause of deficiency        | **Strong** (systematic review of case reports and series)   |
| Drug inhibition of THTR-2                         | **Strong** in vitro; **variable** clinical significance     |
| SIBO contributing to deficiency                   | **Moderate** after bariatric surgery; **limited** elsewhere |
| IBD and coeliac disease                           | **Limited to moderate**; findings mixed                     |
| Folate deficiency impairing thiamine absorption   | **Limited** (animal studies)                                |

## Open questions

* How much do IBD, coeliac disease and other enteropathies reduce thiamine absorption in people, independent of intake?
* Does SIBO outside the bariatric setting meaningfully affect thiamine status?
* Which absorption strategy works best in people with established malabsorption? Comparative studies are lacking.

## Related pages

* [Thiamine Transporters](broken://pages/e114cfc2a7f363a679ae103c52c9089e5d2d0b24)
* [GI Factors Affecting Thiamine Uptake](broken://pages/fa7b936a5a5b06d4438d7966f1ad6f33c65df7e7)
* [Thiamine Derivatives](broken://pages/44390ee2e231e4f690942c9b807cab9f6eb7272d)
* [Causes of Deficiency](broken://pages/e2f0079872756b16d945a693f3b5e16abb5efad9)

## References

1. Said HM. Intestinal absorption of water-soluble vitamins in health and disease. *Biochemical Journal*. 2011;437(3):357–372.
2. Hoyumpa AM Jr. Mechanisms of thiamin deficiency in chronic alcoholism. *American Journal of Clinical Nutrition*. 1980;33(12):2750–2761.
3. Thomson AD, Baker H, Leevy CM. Patterns of ³⁵S-thiamine hydrochloride absorption in the malnourished alcoholic patient. *Journal of Laboratory and Clinical Medicine*. 1970;76(1):34–45.
4. Subramanya SB, Subramanian VS, Said HM. Chronic alcohol consumption and intestinal thiamin absorption: effects on physiological and molecular parameters of the uptake process. *American Journal of Physiology: Gastrointestinal and Liver Physiology*. 2010;299(1):G23–G31.
5. Aasheim ET. Wernicke encephalopathy after bariatric surgery: a systematic review. *Annals of Surgery*. 2008;248(5):714–720.
6. Lakhani SV, et al. Small intestinal bacterial overgrowth and thiamine deficiency after Roux-en-Y gastric bypass surgery in obese patients. *Nutrition Research*. 2008;28(5):293–298.
7. Howard L, Wagner C, Schenker S. Malabsorption of thiamin in folate-deficient rats. *Journal of Nutrition*. 1977;107(5):775–782.
8. Zhang Q, et al. The Janus kinase 2 inhibitor fedratinib inhibits thiamine uptake: a putative mechanism for the onset of Wernicke's encephalopathy. *Drug Metabolism and Disposition*. 2014;42(10):1656–1662.
9. Liang X, et al. Metformin is a substrate and inhibitor of the human thiamine transporter, THTR-2 (SLC19A3). *Molecular Pharmaceutics*. 2015;12(12):4301–4310.
10. Smithline HA, Donnino M, Greenblatt DJ. Pharmacokinetics of high-dose oral thiamine hydrochloride in healthy subjects. *BMC Clinical Pharmacology*. 2012;12:4.
11. Galvin R, et al. EFNS guidelines for diagnosis, therapy and prevention of Wernicke encephalopathy. *European Journal of Neurology*. 2010;17(12):1408–1418.

{% hint style="info" %}
**Editorial note:** This page describes mechanisms and published evidence. It is not medical advice and does not recommend doses. Suggest corrections or new sources via the feedback link.
{% endhint %}
